PULM trade ideas
PULMPulmatrix Inc. (PULM) develops therapies for the treatment of pulmonary diseases. It came public above $20 in March 2014 and entered a severe downtrend that continued into the start of 2017, dropping to an all-time low at 50-cents. The stock went vertical in early February, after meeting Nasdaq exchange compliance issues, and stalled following a 950K secondary offering at $3.50. It looks like new supply has been absorbed, favoring continued upside that could eventually reach double digits.
PULM 2/2/2017 bought at open sold at 5 break PULM has been a monster these past few days kept a close on it during the open and scalped the 5 break. Sold half and rode the rest to 6 and didnt touch it. Alot of the other students bought this big dips at 10 and 1030 but we advised to get out after 12 has there was a change in trend.